With Reverse Merger Complete, Transcept Looks To Partner Intermezzo
Newly public specialty firm anticipates annual U.S. sales of $600 million for middle-of-night sleep aid.
Newly public specialty firm anticipates annual U.S. sales of $600 million for middle-of-night sleep aid.